INVAC-1 Anti-Cancer hTERT DNA Immunotherapy

Phase 1 Completed 26 enrolled Invectys Keyrus Biopharma · collab

NaSingle-groupOpen-labelTreatment

Summary

INVAC-1 is intended to be used for the treatment of adult patients with advanced solid tumors unresponsive to currently available therapies, or for whom no standard therapy is available.

Timeline

Start: 2014-11
Primary completion: 2018-02
Completion: 2018-06-01

Publications

Teixeira L, Medioni J, Garibal J, Adotevi O, Doucet L, Durey MD, Ghrieb Z, Kiladjian JJ, Brizard M, Laheurte C, Wehbe M, Pliquet E, Escande M, Defrance R, Culine S, Oudard S, Wain-Hobson S, Doppler V, Huet T, Langlade-Demoyen P. A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 Feb 1;26(3):588-597. doi: 10.1158/1078-0432.CCR-19-1614. Epub 2019 Sep 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN	Vaccine	100 ug	Intranasal
Subject	INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN	Vaccine	400 ug	Intranasal
Subject	INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN	Vaccine	800 ug	Intranasal

INVAC-1 Anti-Cancer hTERT DNA Immunotherapy

Summary

Timeline

Publications

Drugs

Indications